ES2306610A1 - Use of l-carnitine for treating arterial hypertension - Google Patents
Use of l-carnitine for treating arterial hypertension Download PDFInfo
- Publication number
- ES2306610A1 ES2306610A1 ES200701091A ES200701091A ES2306610A1 ES 2306610 A1 ES2306610 A1 ES 2306610A1 ES 200701091 A ES200701091 A ES 200701091A ES 200701091 A ES200701091 A ES 200701091A ES 2306610 A1 ES2306610 A1 ES 2306610A1
- Authority
- ES
- Spain
- Prior art keywords
- carnitine
- hypertension
- treatment
- sqbullet
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 55
- 208000037849 arterial hypertension Diseases 0.000 title claims abstract description 14
- 229960001518 levocarnitine Drugs 0.000 title 1
- 238000011282 treatment Methods 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims description 30
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000007170 pathology Effects 0.000 abstract description 5
- 241000700159 Rattus Species 0.000 description 17
- 230000001631 hypertensive effect Effects 0.000 description 11
- 229960004203 carnitine Drugs 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010058892 Carnitine deficiency Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000027775 Bronchopulmonary disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000003862 amino acid derivatives Chemical group 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 229940097271 other diuretics in atc Drugs 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Uso de la L-carnitina para el tratamiento de la hipertensión arterial.Use of L-carnitine for Treatment of hypertension.
La presente invención se refiere al uso de la L-carnitina para la elaboración de un medicamento o un suplemento nutricional para el tratamiento o control de la hipertensión arterial. Del mismo modo, esta invención también está referida a composiciones farmacéuticas para el tratamiento de la mencionada patología que comprendan una cantidad terapéuticamente efectiva de L-carnitina.The present invention relates to the use of the L-carnitine for the preparation of a medicine or a nutritional supplement for the treatment or control of arterial hypertension. Similarly, this invention is also referred to pharmaceutical compositions for the treatment of mentioned pathology that understand a therapeutically amount Effective of L-carnitine.
La L-carnitina (L-3-hidroxi-4-N,N,N-trimetilaminobutirato) es un derivado aminoacídico presente en la mayoría de las especies animales y en muchos microorganismos y plantas. Se encuentra ampliamente distribuido por todo el organismo, aunque se presenta en mayores cantidades en el corazón y en el músculo esquelético (Panter R. A. y Mudd J. B. (1969). FEBS Lett. 5(2): 169-170; Rebouche C. J. (1992). FASEB J. 6(15): 3379-3386.).L-carnitine (L-3-hydroxy-4-N, N, N-trimethylaminobutyrate) It is an amino acid derivative present in most species animals and in many microorganisms and plants. It's found widely distributed throughout the body, although it is presented in greater amounts in the heart and skeletal muscle (Panter R. A. and Mudd J. B. (1969). FEBS Lett. 5 (2): 169-170; Rebouche C. J. (1992). PHASEB J. 6 (15): 3379-3386.).
La función principal de este derivado aminoacídico consiste en actuar como cofactor en el transporte de ácidos grasos al interior de la mitocondria, donde se produce la \beta-oxidación de los mismos, para la obtención de energía metabólica (Bremer J. (1983). Physiol. Rev. 63(4): 1420-1480.), desempeñando un papel crucial en el metabolismo de los ácidos grasos.The main function of this derivative amino acid consists in acting as a cofactor in the transport of fatty acids inside the mitochondria, where the β-oxidation thereof, to obtain of metabolic energy (Bremer J. (1983). Physiol. Rev. 63 (4): 1420-1480.), Playing a role crucial in the metabolism of fatty acids.
El 75% de la cantidad de carnitina requerida por el organismo proviene de la dieta. El resto se sintetiza endógenamente en el hígado y en menor cantidad en el riñón y cerebro, a partir de los aminoácidos lisina y metionina (Tanphaichitr V. y Broquist H. P. (1973). Role of lysine and -N-trimethyllysine in carnitine biosynthesis. II. Studies in the rat. J. Biol. Chem. 248(6): 2176-2181.).75% of the amount of carnitine required by The organism comes from the diet. The rest is synthesized endogenously in the liver and in smaller amounts in the kidney and brain, from the amino acids lysine and methionine (Tanphaichitr V. and Broquist H. P. (1973). Role of lysine and -N-trimethyllysine in carnitine biosynthesis. II. Studies in the rat. J. Biol. Chem. 248 (6): 2176-2181.).
La carnitina no es considerada normalmente como un nutriente esencial, debido a que el organismo en condiciones normales es capaz de sintetizar las cantidades necesarias. Sin embargo, en la mayoría de las patologías producidas por una deficiencia de carnitina está justifica esta suplementación con L-carnitina. Las deficiencias de carnitina afectan principalmente al músculo y al corazón, ya que su principal fuente de energía son los ácidos grasos. Por esta razón, el tratamiento con L-carnitina está especialmente indicado en enfermedades musculares y cardiovasculares.Carnitine is not normally considered as an essential nutrient, because the organism in conditions Normal is able to synthesize the necessary amounts. Without However, in most of the pathologies produced by a carnitine deficiency is justified this supplementation with L-carnitine Carnitine deficiencies affect mainly to the muscle and the heart, since its main source of energy are fatty acids. For this reason, the treatment with L-carnitine is especially indicated in muscular and cardiovascular diseases.
Las aplicaciones clínicas de la L-carnitina según el Vademécum Médico Internacional (edición 43, 2002) son:The clinical applications of the L-carnitine according to the International Medical Vademecum (edition 43, 2002) are:
- \sqbullet\ sqbullet
- Miopatías causadas por una deficiencia de L-carnitina. Myopathies caused by a L-carnitine deficiency.
- \sqbullet\ sqbullet
- Cardiomiopatías producidas por una deficiencia de L-carnitina. Cardiomyopathies produced due to a deficiency of L-carnitine.
- \sqbullet\ sqbullet
- Pérdida secundaria de carnitina durante la hemodiálisis. Secondary loss of Carnitine during hemodialysis.
- \sqbullet\ sqbullet
- Miocardiopatías producidas por adrimicina y antidepresivos tricíclicos. Cardiomyopathies produced by adrimycin and tricyclic antidepressants.
- \sqbullet\ sqbullet
- Isquemia miocárdica aguda y crónica: angina de pecho, secuelas de infarto de miocardio, insuficiencia cardíaca, corazón senil, cardiopatía congestiva, arritmias, etc. Acute myocardial ischemia and Chronic: angina pectoris, sequelae of myocardial infarction, heart failure, senile heart, congestive heart disease, arrhythmias, etc.
En las cuatro primeras indicaciones, el tratamiento con L-carnitina ayuda a paliar la sintomatología producida por la carencia de la misma. En el caso de las isquemias, el tratamiento con L-carnitina mejora la recuperación de los pacientes, aliviando los síntomas, reduciendo el requerimiento de otros fármacos y disminuyendo la mortalidad.In the first four indications, the L-carnitine treatment helps to alleviate the symptomatology produced by the lack thereof. In the case of Ischemia, treatment with L-carnitine improves patient recovery, relieving symptoms, reducing the requirement of other drugs and decreasing the mortality.
Además de las indicaciones terapéuticas mencionadas, existen muchos estudios que sugieren el uso de L-carnitina y algunos acil-derivados en otras patologías. Así, varios estudios sugieren que el tratamiento con L-carnitina o propionil-L-carnitina puede mejorar una condición llamada claudicación intermitente, que cursa con dolores en las piernas al caminar debido a un estrechamiento arterial (Brevetti G., et al (1988). Circulation. 77(4): 767-773.; Brevetti G., et al (1992). Eur. Heart J. 13(2): 251-255.; Dean S. M. (2002). Vasc. Med. 7(4): 301-309.).In addition to the therapeutic indications mentioned, there are many studies that suggest the use of L-carnitine and some acyl derivatives in other pathologies. Thus, several studies suggest that treatment with L-carnitine or propionyl-L-carnitine may improve a condition called intermittent claudication, which causes leg pain when walking due to arterial narrowing (Brevetti G., et al (1988) .Circulation. 77 (4): 767-773 .; Brevetti G., et al (1992). Eur. Heart J. 13 (2): 251-255 .; Dean SM (2002). Vasc. Med. 7 ( 4): 301-309.).
De la misma forma, se ha demostrado su utilidad para mejorar la tolerancia al ejercicio en personas que sufren enfermedad bronco-pulmonar obstructiva crónica (EBPOC), mejor conocida como enfisema (Dal Negro R., et al (1988). Int. J. Clin. Pharmacol. Ther. Toxicol. 26(5): 269-272; Montgomery S. A., et al (2003). Int. Clin. Psychopharmacol. 18(2): 61-71); en la demencia senil (Bella R., et al (1990). Int. J. Clin. Pharmacol. Res. 10(6): 355-360.); en algunos casos de enfermos de ataxia (Gallagher C., et al L. (2002). J. Child Neurol. 17(6): 453-456.); en niños con beta talasemia mayor, donde demostraron que el tratamiento con L-carnitina reducía la necesidad de transfusiones sanguíneas (Yesilipek M. A., et al (1998) Acta Haematol. 100(3): 162-163.); en la fatiga crónica (Kuratsune H., et al (2002) Neuroimage. 17(3): 1256-1265); en la terapéutica de la infertilidad (Lenzi A., et al (2003). Fertil. Steril. 79(2): 292-300); en el control de la glucemia en personas que padecen diabetes (Mingrone G., et al. J. Am. Coll. Nutr. 18(1): 77-82.), contribuyendo a prevenir las posibles complicaciones, principalmente las cardiovasculares.In the same way, it has been proven useful for improving exercise tolerance in people suffering from chronic obstructive broncho-pulmonary disease (EBPOC), better known as emphysema (Dal Negro R., et al (1988). Int. J. Clin. Pharmacol. Ther. Toxicol. 26 (5): 269-272; Montgomery SA, et al (2003). Int. Clin. Psychopharmacol. 18 (2): 61-71); in senile dementia (Bella R., et al (1990). Int. J. Clin. Pharmacol. Res. 10 (6): 355-360.); in some cases of patients with ataxia (Gallagher C., et al L. (2002). J. Child Neurol. 17 (6): 453-456.); in children with beta thalassemia major, where they demonstrated that treatment with L-carnitine reduced the need for blood transfusions (Yesilipek MA, et al (1998) Acta Haematol. 100 (3): 162-163.); in chronic fatigue (Kuratsune H., et al (2002) Neuroimage. 17 (3): 1256-1265); in the therapy of infertility (Lenzi A., et al (2003). Fertil. Steril. 79 (2): 292-300); in glycemic control in people suffering from diabetes (Mingrone G., et al . J. Am. Coll. Nutr. 18 (1): 77-82.), contributing to prevent possible complications, mainly cardiovascular ones.
La utilidad del tratamiento con carnitina también se está abordando en el campo de las cirrosis, donde existen numerosas discrepancias (Selimoglu M. A., et al (2001). Plasma and liver carnitine status of children with chronic liver diseases and cirrhosis. Pediatr. Int. 43(4): 391-395.), y en las neuropatías periféricas, donde se están realizando estudios con la acetil-L-carnitina (Scarpini E., et al. Peripher. Nerv. Syst. 2(3): 250-252.). También se está estudiando el posible efecto beneficioso de la carnitina en enfermos de cáncer, ya que en muchos casos existe una deficiencia de la misma debida a los cambios metabólicos causados bien por la propia neoplasia o por la terapia antineoplásica (Graziano F., et al (2002). Br. J. Cancer. 86(12): 1854-1857.).The usefulness of carnitine treatment is also being addressed in the field of cirrhosis, where there are numerous discrepancies (Selimoglu MA, et al (2001). Plasma and liver carnitine status of children with chronic liver diseases and cirrhosis. Pediatr. Int. 43 (4): 391-395.), And in peripheral neuropathies, where studies are being conducted with acetyl-L-carnitine (Scarpini E., et al . Peripher. Nerv. Syst. 2 (3): 250-252 .). The possible beneficial effect of carnitine in cancer patients is also being studied, since in many cases there is a deficiency due to metabolic changes caused either by the neoplasm itself or by the antineoplastic therapy (Graziano F., et al (2002) Br. J. Cancer. 86 (12): 1854-1857.).
Actualmente, existen en la industria farmacéutica multitud de medicamentos que actúan como antihipertensivos, citando entre otros diuréticos, betabloqueantes, IECA (inhibidores de la enzima convertidora de la angiotensina I) y ARA II (antagonistas de los receptores de angiotensina II) ("Guía Española de Hipertensión Arterial 2005". Hipertensión, 22, Suplemento 2, 2005.19). La toma de decisión del tratamiento antihipertensivo está basada en el grado de la hipertensión arterial (normal-alta, grado 1, grado 2 y grado 3) y en la asociación con otros factores de riesgos como episodios cardiovasculares, diabetes ó insuficiencia renal ("Guía Española de Hipertensión Arterial 2005". Hipertensión, 22, Suplemento 2, 2005.19). Sin embargo, en todos los grados de hipertensión arterial, a excepción del grado 3, y según esté ó no asociado a factores de riesgos ("Guía Española de Hipertensión Arterial 2005". Hipertensión, 22, Suplemento 2, 2005.19), recomienda el uso de un tratamiento no farmacológico, o dicho de otra forma, adoptar cambios en el estilo de vida, complementado ó no con tratamiento farmacológico, para llegar a normalizar las cifras de tensión arterial y de esa forma prevenir el desarrollo de enfermedades cardiovasculares. Entre los cambios en el estilo de vida, la alimentación desempeña un papel fundamental en el tratamiento de la hipertensión arterial, como lo demuestran los estudios DASH y INTERSALT, sobre el beneficio del uso de verduras, pescado, frutas, grasas no saturadas y restricción de sal para el control de la presión arterial ("Guía Española de Hipertensión Arterial 2005". Hipertensión, 22, Suplemento 2, 2005.19).Currently, they exist in the industry pharmaceutical multitude of medications that act as antihypertensives, citing among other diuretics, beta blockers, ACEI (angiotensin I converting enzyme inhibitors) and ARA II (angiotensin II receptor antagonists) ("Guide Spanish of Arterial Hypertension 2005 ". Hypertension, 22, Supplement 2, 2005.19). The decision making of the treatment antihypertensive is based on the degree of hypertension (normal-high, grade 1, grade 2 and grade 3) and in the association with other risk factors such as episodes cardiovascular, diabetes or renal failure ("Spanish Guide of Hypertension 2005 ". Hypertension, 22, Supplement 2, 2005.19). However, in all degrees of hypertension arterial, with the exception of grade 3, and depending on whether or not it is associated with risk factors ("Spanish Guide to Arterial Hypertension 2005 ". Hypertension, 22, Supplement 2, 2005.19), recommends the use of a non-drug treatment, or in other words, adopt changes in lifestyle, complemented or not with pharmacological treatment, to get to normalize the figures of blood pressure and thereby prevent the development of cardiovascular diseases. Among the changes in the style of life, food plays a fundamental role in the treatment of high blood pressure, as evidenced by DASH and INTERSALT studies, on the benefit of using vegetables, fish, fruits, unsaturated fats and salt restriction for blood pressure control ("Spanish Guide to Hypertension Arterial 2005 ". Hypertension, 22, Supplement 2, 2005.19).
Los autores de la presente invención han descubierto, sorprendentemente, que la L-Carnitina lleva a cabo una función de control sobre la hipertensión arterial, pudiendo constituir ésta un suplemento nutricional que ayude al control de la mencionada patología, así como usarse junto, a otros antihipertensivos, como coadyuvante para un mayor control de la hipertensión arterial.The authors of the present invention have surprisingly discovered that L-Carnitine performs a control function on arterial hypertension, This may constitute a nutritional supplement that helps the control of the mentioned pathology, as well as being used together with others antihypertensives, as an adjuvant for greater control of the arterial hypertension.
La hipertensión arterial (HTA) constituye el principal factor de riesgo para las enfermedades cardiovasculares en los países occidentales, siendo uno de los principales problemas socio-sanitarios de las sociedades industrializadas. En España, los últimos datos de mortalidad analizados demuestran que la hipertensión arterial es responsable de una de cada cuatro muertes, de las cuales, una de cada 2,5 es debida a causa cardiovascular (Banegas J.R., y Rodríguez F. (2002). Rev. Clin. Esp. 202 (1): 12-15.). Además, es importante señalar el hecho de que en los pacientes hipertensos se produce una acumulación de otros factores de riesgo para las enfermedades cardiovasculares, como hipercolesterolemia, hipertrigliceridemia, diabetes mellitus e hiperinsulinemia basal o síndrome de insulinorresistencia (Almodóvar C. et al (1996) Asociación de los factores de riesgo metabólico y presiones arteriales en una población natural (Mora de Toledo). Atención Primaria 17: 458-462.).Arterial hypertension (hypertension) constitutes the main risk factor for cardiovascular diseases in Western countries, being one of the main socio-health problems of industrialized societies. In Spain, the latest mortality data analyzed show that arterial hypertension is responsible for one in four deaths, of which one in 2.5 is due to cardiovascular causes (Banegas JR, and Rodríguez F. (2002). Rev. Clin. Esp. 202 (1): 12-15.). In addition, it is important to note the fact that in hypertensive patients there is an accumulation of other risk factors for cardiovascular diseases, such as hypercholesterolemia, hypertriglyceridemia, diabetes mellitus and basal hyperinsulinemia or insulin resistance syndrome (Almodóvar C. et al (1996) Association of metabolic risk factors and arterial pressures in a natural population (Mora de Toledo). Primary Care 17: 458-462.).
Según lo indicado previamente, existen medicamentos muy eficaces para el control de la presión arterial, sin embargo a pesar de ello, hay un alto porcentaje de la población cuyos niveles de presión arterial no llegan a controlarse, de forma que por una u otra causa, sólo se consigue controlar la HTA en menos de un 50% de los enfermos hipertensos.As previously indicated, there are very effective medications for blood pressure control, However, despite this, there is a high percentage of the population whose blood pressure levels are not controlled, so that for one reason or another, you can only control the HTA in less than 50% of hypertensive patients.
Así la presente invención aporta un nuevo uso para la L-carnitina como producto para el control de la hipertensión. De este modo, la L-canitina podría emplearse como producto funcional, como suplemento en la dieta ó bien mediante la utilización de formas farmacéuticas, para ayudar al control de la hipertensión arterial. Cabría decir que el consumo de L-carnitina podría no ser un sustituto de aquellos medicamentos dirigidos a reducir la presión arterial, así como de las medidas higiénico-dietéticas para mejorar los niveles de presión arterial, sin embargo, su utilización bien sola ó combinación con otras terapias antihipertensiva, podría realizar un efecto coadyuvante al control de la tensión arterial, dado su efecto hipotensor o anti-hipertensivo. A todo ello habría que añadir la baja toxicidad que presenta la L-carnitina, así como la falta de efectos secundarios, la cual la hace candidata perfecta como suplemento a aplicar en las personas hipertensas.Thus the present invention brings a new use for L-carnitine as a control product of hypertension Thus, the L-canitine could be used as a functional product, as a supplement in the diet or by using pharmaceutical forms, to Help control hypertension. It could be said that the L-carnitine consumption may not be a substitute of those medications aimed at reducing blood pressure, as well as hygienic-dietary measures to improve blood pressure levels however your use either alone or in combination with other therapies antihypertensive, could perform an adjuvant effect to the control of blood pressure, given its hypotensive effect or anti-hypertensive To all this we should add the low toxicity of L-carnitine, as well such as the lack of side effects, which makes her a candidate Perfect as a supplement to apply in hypertensive people.
Así, un primer aspecto de la invención se relaciona con el uso de la L-carnitina para la elaboración de un medicamento para el tratamiento de la hipertensión arterial.Thus, a first aspect of the invention is relates to the use of L-carnitine for development of a medicine for the treatment of arterial hypertension.
Un segundo aspecto de la invención se relaciona con el uso de la L-carnitina como coadyuvante en una composición farmacéutica para el tratamiento de la hipertensión arterial.A second aspect of the invention relates to with the use of L-carnitine as an adjuvant in a pharmaceutical composition for the treatment of hypertension arterial.
Un tercer aspecto de la invención se relaciona con el uso de la L-carnitina para la elaboración de un suplemento nutricional para el tratamiento o control de la hipertensión arterial.A third aspect of the invention relates to with the use of L-carnitine for the elaboration of a nutritional supplement for the treatment or control of arterial hypertension.
Un cuarto aspecto de la invención se relaciona con una composición farmacéutica para el tratamiento de la hipertensión arterial que comprende L-carnitina en una cantidad terapéuticamente efectiva. En una realización preferida de este aspecto de la invención la composición farmacéutica además comprende otros agentes para el tratamiento de la hipertensión arterial o antihipertensivos.A fourth aspect of the invention relates to with a pharmaceutical composition for the treatment of arterial hypertension comprising L-carnitine in a therapeutically effective amount. In one embodiment preferred of this aspect of the invention the composition Pharmaceutical also includes other agents for the treatment of hypertension or antihypertensives.
\global\parskip0.950000\baselineskip\ global \ parskip0.950000 \ baselineskip
La figura 1 muestra el análisis de la presión
diastólica (mm de Hg) para ratas que han sido tratadas con 300
de
L-carnitina mg/kg. La columna A
representa un grupo de ratas normotensas no tratadas con
L-carnitina, la columna B un grupo de ratas
hipertensas no tratadas con L-carnitina, la columna
C un grupo de ratas normotensas tratadas con
L-carnitina, y la columna D grupo de un ratas
hipertensas tratadas con L-carnitina.Figure 1 shows the analysis of diastolic pressure (mm Hg) for rats that have been treated with 300
L-carnitine mg / kg. Column A represents a group of normotensive rats not treated with L-carnitine, column B a group of hypertensive rats not treated with L-carnitine, column C a group of normotensive rats treated with
L-carnitine, and column D group of a hypertensive rats treated with L-carnitine.
La figura 2 muestra el análisis de la presión
sistólica (mm de Hg) para ratas que han sido tratadas con 300
de
L-carnitina mg/kg. La columna A
representa un grupo de ratas normotensas no tratadas con
L-carnitina, la columna B un grupo de ratas
hipertensas no tratadas con L-carnitina, la columna
C un grupo de ratas normotensas tratadas con
L-carnitina, y la columna D grupo de un ratas
hipertensas tratadas con L-carnitina.Figure 2 shows the analysis of systolic pressure (mm Hg) for rats that have been treated with 300
L-carnitine mg / kg. Column A represents a group of normotensive rats not treated with L-carnitine, column B a group of hypertensive rats not treated with L-carnitine, column C a group of normotensive rats treated with
L-carnitine, and column D group of a hypertensive rats treated with L-carnitine.
A continuación se detallan los ejemplos de realización de la invención, los cuales no limitan la invención, sino que su finalidad es ilustrarla, poniendo de manifiesto la capacidad de la L-carnitina para actuar como hipotensor.The examples of embodiment of the invention, which do not limit the invention, but its purpose is to illustrate it, highlighting the L-carnitine's ability to act as hypotensive
La invención se llevó a cabo usando ratas hipertensas y normotensas de edades comprendidas entre 20-22 semanas. A esta edad las ratas hipertensas presentan una hipertensión continua y mantenida. Se realizaron cuatro grupos experimentales de animales:The invention was carried out using rats hypertensive and normotensive women aged between 20-22 weeks At this age hypertensive rats have a continuous and sustained hypertension. They were made Four experimental groups of animals:
- \sqbullet\ sqbullet
- Grupo A: ratas normotensas no tratadas con L-carnitina. Group A: Normotensive rats no treated with L-carnitine.
- \sqbullet\ sqbullet
- Grupo B: ratas hipertensas no tratadas con L-carnitina. Group B: non-hypertensive rats treated with L-carnitine.
- \sqbullet\ sqbullet
- Grupo C: ratas normotensas tratadas con L-carnitina. Group C: normotensive rats treated with L-carnitine.
- \sqbullet\ sqbullet
- Grupo D: ratas hipertensas tratadas con L-carnitina. Group D: hypertensive rats treated with L-carnitine.
El tratamiento con L-carnitina consistió en administrar en agua de bebida 300 mg de L-carnitina/Kg de peso corporal durante un periodo de 12 semanas. Una vez transcurrido este tiempo, realizamos medida de la presión arterial sistólica y diastólica. Los resultados obtenidos fueron:L-carnitine treatment consisted of administering 300 mg of drinking water in L-carnitine / Kg body weight over a period 12 weeks After this time, we measure of systolic and diastolic blood pressure. The results obtained were:
Presión sistólica (Figura 2):Systolic pressure (Figure 2):
- \sqbullet\ sqbullet
- grupo A: 166,6 \pm 1,6 mm de Hg group A: 166.6 ± 1.6 mm from Hg
- \sqbullet\ sqbullet
- grupo B: 238,5 \pm 2,2 mm de Hg group B: 238.5 ± 2.2 mm from Hg
- \sqbullet\ sqbullet
- grupo C: 167,3 \pm 1,3 mm de Hg group C: 167.3 ± 1.3 mm from Hg
- \sqbullet\ sqbullet
- grupo D: 191,5 \pm 2,6 mm de Hg group D: 191.5 ± 2.6 mm from Hg
Una vez realizado el test de ANOVA se obtuvo una p<0.0001. Aplicando el análisis por test de Student-Newman-Keuls de comparación pareada se obtuvieron las siguientes significaciones:Once the ANOVA test was performed, a p <0.0001. Applying the analysis by test of Student-Newman-Keuls comparison paired the following meanings were obtained:
- \sqbullet\ sqbullet
- A-B: p<0.001 A-B: p <0.001
- \sqbullet\ sqbullet
- A-D: p<0.001 A-D: p <0.001
- \sqbullet\ sqbullet
- B-C: p< 0.001 B-C: p < 0.001
- \sqbullet\ sqbullet
- B-D: p< 0.001 B-D: p < 0.001
- \sqbullet\ sqbullet
- C-D: p< 0.001 C-D: p < 0.001
Presión diastólica (Figura 1):Diastolic pressure (Figure 1):
- \sqbullet\ sqbullet
- grupo A: 127,7 \pm 0,7 mm de Hg group A: 127.7 ± 0.7 mm from Hg
- \sqbullet\ sqbullet
- grupo B: 205,5 \pm 1,0 mm de Hg group B: 205.5 ± 1.0 mm from Hg
- \sqbullet\ sqbullet
- grupo C: 138,1 \pm 0,4 mm de Hg group C: 138.1 ± 0.4 mm from Hg
- \sqbullet\ sqbullet
- grupo D: 167,7 \pm 2,1 mm de Hg group D: 167.7 ± 2.1 mm from Hg
\global\parskip1.000000\baselineskip\ global \ parskip1.000000 \ baselineskip
Una vez realizado el test de ANOVA se obtuvo una p<0.0001. Aplicando el análisis por test de Student-Newman-Keuls de comparación pareada se obtuvieron las siguientes significaciones:Once the ANOVA test was performed, a p <0.0001. Applying the analysis by test of Student-Newman-Keuls comparison paired the following meanings were obtained:
- \sqbullet\ sqbullet
- A-B: p<0.001 A-B: p <0.001
- \sqbullet\ sqbullet
- A-D: p<0.001 A-D: p <0.001
- \sqbullet\ sqbullet
- B-C: p< 0.001 B-C: p < 0.001
- \sqbullet\ sqbullet
- B-D: p< 0.001 B-D: p < 0.001
- \sqbullet\ sqbullet
- C-D: p< 0.001 C-D: p < 0.001
Estos resultados muestran que la administración diaria de 300 mg/kg peso corporal de L-carnitina durante 12 semanas, disminuye la presión arterial diastólica en un 56% y la sistólica en un 66%, lo que demuestra el efecto hipotensor de la L-carnitina.These results show that the administration 300 mg / kg daily body weight of L-carnitine for 12 weeks, the diastolic blood pressure drops by 56% and systolic in 66%, demonstrating the hypotensive effect of L-carnitine.
Claims (5)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200701091A ES2306610B1 (en) | 2007-04-16 | 2007-04-16 | USE OF L-CARNITINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION. |
| PCT/ES2008/000249 WO2008125714A1 (en) | 2007-04-16 | 2008-04-15 | Use of l-carnitine for treating arterial hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200701091A ES2306610B1 (en) | 2007-04-16 | 2007-04-16 | USE OF L-CARNITINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2306610A1 true ES2306610A1 (en) | 2008-11-01 |
| ES2306610B1 ES2306610B1 (en) | 2009-09-11 |
Family
ID=39863300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200701091A Active ES2306610B1 (en) | 2007-04-16 | 2007-04-16 | USE OF L-CARNITINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2306610B1 (en) |
| WO (1) | WO2008125714A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011004038A1 (en) * | 2009-07-07 | 2011-01-13 | Universidad De Sevilla | Use of l-carnitine for preventing inflammatory cardiac damage associated with arterial hypertension |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2632619C1 (en) * | 2016-04-20 | 2017-10-06 | Владимир Павлович Лобко | Method for treatment of patients with arterial hypertension |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599232A (en) * | 1983-02-16 | 1986-07-08 | Sigma Tau Industrie Faramaceutiche Riunite S.P.A. | Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy |
| WO2000027386A1 (en) * | 1998-11-11 | 2000-05-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation |
| US20070072927A1 (en) * | 1999-09-23 | 2007-03-29 | Vita Joseph A | Nutritional supplement for increased energy and stamina |
-
2007
- 2007-04-16 ES ES200701091A patent/ES2306610B1/en active Active
-
2008
- 2008-04-15 WO PCT/ES2008/000249 patent/WO2008125714A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599232A (en) * | 1983-02-16 | 1986-07-08 | Sigma Tau Industrie Faramaceutiche Riunite S.P.A. | Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy |
| WO2000027386A1 (en) * | 1998-11-11 | 2000-05-18 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of propionylcarnitine for the manufacture of a medicament for inhibiting smooth muscle cell proliferation |
| US20070072927A1 (en) * | 1999-09-23 | 2007-03-29 | Vita Joseph A | Nutritional supplement for increased energy and stamina |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011004038A1 (en) * | 2009-07-07 | 2011-01-13 | Universidad De Sevilla | Use of l-carnitine for preventing inflammatory cardiac damage associated with arterial hypertension |
| ES2351753A1 (en) * | 2009-07-07 | 2011-02-10 | Universidad De Sevilla | Use of l-carnitine for preventing inflammatory cardiac damage associated with arterial hypertension |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2306610B1 (en) | 2009-09-11 |
| WO2008125714A1 (en) | 2008-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2832506T3 (en) | Compositions comprising nicotinamide riboside and a urolithin | |
| ES2374260T3 (en) | COMPOSITIONS TO INCREASE LIVE ENERGY. | |
| US8318805B2 (en) | Modulation of nitric oxide synthases by betaines | |
| BR112021002855A2 (en) | compositions and methods using at least one glycine or a derivative thereof, at least one n-acetylcysteine or a derivative thereof, and at least one nicotinamide riboside or a nad+ precursor | |
| ES2487647T3 (en) | Combination composition comprising, as active ingredient, L-carnitine or propionyl-L-carnitine, for the prevention or treatment of chronic venous insufficiency | |
| ES2393534T3 (en) | Use of amino acid based compositions for the treatment of sarcopenia | |
| Yakushev et al. | Studying dose-dependent endothelio-and cardioprotective activity of selective arginase II inhibitor in hyperhomocysteine-induced endothelial dysfunction | |
| CN114392228A (en) | Long-lasting formulations of melatonin injections exhibiting long-term stability | |
| BR112020023132A2 (en) | compositions and methods using a nicotinamide precursor adenine dinucleotide (nad +) and at least one ketone or a ketone precursor | |
| EA036702B1 (en) | Mixture of carboxylic acids for treating patients with kidney failure | |
| US20160303177A1 (en) | Nutritional supplement | |
| EP1964566A1 (en) | Preparation with improved bioabsorbability of sapropterin hydrochloride | |
| RU2582962C1 (en) | Agent for preventing and treating neurodegenerative pathology and vascular dementia (versions) | |
| US20160303176A1 (en) | Nutritional supplement | |
| ES2306610B1 (en) | USE OF L-CARNITINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION. | |
| CN1460102A (en) | Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same | |
| Bottiglieri et al. | S-adenosylmethionine | |
| US20200237812A1 (en) | Compound and Composition for Use in the Preventive and/or Curative Treatment of Diseases of the Central Nervous System Characterised by a Decline in Neuronal Plasticity, in Particular Characterised by a Decline in Synaptic Plasticity | |
| US20130065823A1 (en) | Supplement for Strengthening the Muscles of a Human | |
| BR112021004535A2 (en) | powders containing a buffer salt and an amino acid, reconstitution of such powder into a nutritional product, and methods of using such a nutritional product | |
| Guta | Is taurine a pharmaconutrient | |
| CA2959109A1 (en) | Method for enhancing energy production and metabolism in cells | |
| ES2570433B1 (en) | USE OF PROANTOCIANIDINS FOR THE SUPPRESSION OF THE APPETITE OR INDUCTION OF THE COMPANY | |
| AU2018210739B2 (en) | Phenylcreatine, its use and method for its production | |
| ES2917623T3 (en) | Compound and composition for use in the treatment of premenstrual syndrome and/or premenstrual dysphoric disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20081101 Kind code of ref document: A1 |